Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of “Hold” from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has received a consensus rating of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $33.1667.

Several research analysts have recently commented on the stock. Mizuho lowered their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. HC Wainwright started coverage on shares of Upstream Bio in a research note on Wednesday, June 3rd. They set a “buy” rating and a $36.00 target price on the stock. Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. cut shares of Upstream Bio from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $8.00 in a research report on Friday, June 12th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UPB. Norges Bank acquired a new position in Upstream Bio during the 4th quarter worth $78,264,000. Vanguard Group Inc. increased its holdings in Upstream Bio by 12.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock worth $45,944,000 after purchasing an additional 271,718 shares during the period. UBS Group AG raised its position in Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Upstream Bio in the 4th quarter valued at about $41,423,000. Finally, State Street Corp boosted its stake in shares of Upstream Bio by 18.4% in the 4th quarter. State Street Corp now owns 1,319,226 shares of the company’s stock valued at $35,817,000 after buying an additional 204,645 shares during the period.

Upstream Bio Trading Up 2.5%

UPB opened at $6.57 on Friday. The stock’s 50-day moving average price is $7.04 and its 200 day moving average price is $11.65. Upstream Bio has a 12-month low of $5.85 and a 12-month high of $33.68. The firm has a market cap of $357.54 million, a price-to-earnings ratio of -2.26 and a beta of 1.23.

Upstream Bio (NASDAQ:UPB) last released its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. On average, research analysts forecast that Upstream Bio will post -2.9 earnings per share for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.